- Tytuł:
- Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.
- Autorzy:
- Źródło:
- PloS one [PLoS One] 2022 Nov 15; Vol. 17 (11), pp. e0277706. Date of Electronic Publication: 2022 Nov 15 (Print Publication: 2022).
- Typ publikacji:
- Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
Non-alcoholic Fatty Liver Disease*/complications
Non-alcoholic Fatty Liver Disease*/diagnosis
Non-alcoholic Fatty Liver Disease*/drug therapy
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/metabolismCardiovascular Diseases */metabolism
Humans ; PPAR alpha/metabolism ; PPAR gamma/metabolism ; Risk Factors ; Hypoglycemic Agents/therapeutic use ; Liver/metabolism ; Liver Cirrhosis/complications ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/drug therapy ; Heart Disease Risk Factors
Czasopismo naukowe